Shearman & Sterling advised Goldman Sachs in connection with the follow-on public offering by Inspire Medical Systems. of 1,150,000 shares of common stock at a public offering price of $215.00 per share, resulting in aggregate gross proceeds to Inspire of approximately $247.2 million. The offering included 150,000 shares sold pursuant to the exercise in full of the option to purchase additional shares granted by Inspire in connection with the offering.

Goldman Sachs acted as sole book-running manager for the offering.

Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. The Company’s proprietary Inspire system is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

The Shearman & Sterling team below was supported by associate Jordan Briggs (New York-Financial Institutions Advisory & Financial Regulatory.

The Team